Sick Days Decreased in Psoriasis Patients on EtanerceptSick Days Decreased in Psoriasis Patients on Etanercept
This study examined the economic effect of etanercept therapy on patients with psoriasis and psoriatic arthritis. Can it reduce missed work days and improve employment outcomes? BMC Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 17, 2014 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news
Etanercept Plus Methotrexate More Effective on PsoriasisEtanercept Plus Methotrexate More Effective on Psoriasis
According to a new review, there's generally only weak evidence for combining systemic therapies for psoriasis, except for one pairing: etanercept plus methotrexate. Reuters Health Information (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - September 12, 2014 Category: Dermatology Tags: Dermatology News Source Type: news
TNF-alpha Inhibition May Improve Psoriasis, CVD RiskTNF-alpha Inhibition May Improve Psoriasis, CVD Risk
Dr. Graeme M. Lipper reviews a study showing that etanercept produced a reduction in 6 proinflammatory markers. Medscape Dermatology (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 4, 2014 Category: Allergy & Immunology Tags: Dermatology Viewpoint Source Type: news
Lilly psoriasis drug impresses; battle nears with Amgen, Novartis
(Reuters) - An experimental new psoriasis treatment from Eli Lilly and Co proved superior to Amgen Inc's blockbuster Enbrel, drawing it closer to a potential marketing battle with new products being developed by Amgen and Novartis AG. (Source: Reuters: Health)
Source: Reuters: Health - August 21, 2014 Category: Consumer Health News Tags: healthNews Source Type: news
Progress in the treatment of early-stage inflammatory joint disease
Pfizer has announced that the European Commission has granted a licence extension for Enbrel (etanercept) in the treatment of adult patients with severe non-radiographic axial spondyloarthritis. (Source: Pharmacy Europe)
Source: Pharmacy Europe - August 6, 2014 Category: Drugs & Pharmacology Authors: AMcculloch Tags: *** Editor's Pick Rheumatology early-stage inflammatory joint disease enbrel etanercept Featured Articles pfizer Source Type: news
Arthritis drug Etanercept could also halt Alzheimer's
Twenty women and men were given Etanercept and found the ability to carry out vital everyday tasks such as washing and dressing did not worsen. (Source: the Mail online | Health)
Source: the Mail online | Health - July 17, 2014 Category: Consumer Health News Source Type: news
Inducing Remission in Early Inflammatory ArthritisInducing Remission in Early Inflammatory Arthritis
Does adding etanercept to methotrexate offer any advantages with respect to remission in patients with early inflammatory arthritis? Medscape Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 2, 2014 Category: Consumer Health News Tags: Rheumatology Viewpoint Source Type: news
EU's CHMP Endorses New Indication for Etanercept (Enbrel)EU's CHMP Endorses New Indication for Etanercept (Enbrel)
The EMA Committee has recommended etanercept for adults with severe nonradiographic axial spondyloarthritis with objective signs of inflammation and/or imaging evidence who fail other therapies. International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 30, 2014 Category: Consumer Health News Tags: Rheumatology News Source Type: news
Biosimilars in Rheumatoid Arthritis: Wave of the Future?Biosimilars in Rheumatoid Arthritis: Wave of the Future?
The biosimilars of etanercept and infliximab are equivalent to their respective reference biologics, new research shows, but the jury is still out on how big an impact biosimilars will have. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 13, 2014 Category: Consumer Health News Tags: Rheumatology News Source Type: news
Biosimilars for RA Succeed in Phase III
PARIS (MedPage Today) -- Two antitumor necrosis factor blockers that were biosimilar to the proprietary agents etanercept (Enbrel) and infliximab (Remicade) were equivalent in efficacy to the original biologic formulations in patients with active rheumatoid arthritis, phase III trials demonstrated. (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - June 12, 2014 Category: Geriatrics Source Type: news
Potential anti-TNF response biomarker identified
DNA methylation has been identified as a potential biomarker of response to etanercept and adalimumab in patients with rheumatoid arthritis according to preliminary results from one of the largest methylome-wide investigations of treatment response to anti-TNF therapies. This data bring clinicians a step closer to being able to personalize a patient's treatment pathway. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 12, 2014 Category: Science Source Type: news
Potential anti-TNF response biomarker identified
(European League Against Rheumatism) DNA methylation has been identified as a potential biomarker of response to etanercept and adalimumab in patients with rheumatoid arthritis according to preliminary results from one of the largest methylome-wide investigations of treatment response to anti-TNF therapies. This data, presented today at the European League Against Rheumatism Annual Congress, bring clinicians a step closer to being able to personalise a patient's treatment pathway. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 12, 2014 Category: Global & Universal Source Type: news
Etanercept Benefits Seem Limited in Early ArthritisEtanercept Benefits Seem Limited in Early Arthritis
In patients with early rheumatoid arthritis receiving treatment with methotrexate and prednisone (COBRA-light) or the same agents along with sulfasalazine (COBRA), adding etanercept is not of notable benefit. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 3, 2014 Category: Consumer Health News Tags: Rheumatology News Source Type: news
Enbrel Eases Nonradiographic Spinal Pain
(MedPage Today) -- Patients with early axial spondyloarthritis who had not yet developed sacroiliitis visible on x-rays nonetheless benefited from treatment with etanercept (Enbrel), a phase IIIb clinical trial found. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - May 31, 2014 Category: Primary Care Source Type: news
Humira, Enbrel costs highest in the United States
Read the full story on MD Consult:
Humira, Enbrel costs highest in the United States (Source: MD Consult: News: Top Stories)
Source: MD Consult: News: Top Stories - May 14, 2014 Category: Journals (General) Source Type: news
